MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
2.810
-0.050
-1.75%
Closed 19:34 08/10 EDT
OPEN
2.810
PREV CLOSE
2.860
HIGH
2.860
LOW
2.720
VOLUME
71.88K
TURNOVER
0
52 WEEK HIGH
4.980
52 WEEK LOW
1.110
MARKET CAP
35.85M
P/E (TTM)
-1.9418
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LTRN last week (0803-0807)?
Weekly Report · 1d ago
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results
Barchart · 3d ago
Press Release: Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
Dow Jones · 4d ago
Lantern Pharma Spins Off Open-Medicine AI Platform
TipRanks · 08/03 22:18
Lantern Pharma establishes Open-Medicine AI as separate company
TipRanks · 08/03 11:36
Lantern Pharma Creates Open-Medicine AI As Separate Entity
Benzinga · 08/03 11:34
Weekly Report: what happened at LTRN last week (0727-0731)?
Weekly Report · 08/03 09:14
New to The Street TV Announces Broadcast of Show No. 765 Tonight on Bloomberg Television at 6:30 PM ET Featuring Envoy Medical, Graphene Manufacturing Group, Rhino Bitcoin, and Big Sky Industrial
Barchart · 08/01 10:30
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.